

Review of: "Sotorasib Treatment Could Worsen the Prognosis of Advanced KRASG12C-Mutated Non-Small Cell Lung Cancer"

Nagaraj Gowda¹

¹ Head, Research and Development, Glenmark Pharmaceuticals, Mumbai, India

Potential competing interests: No potential competing interests to declare.

Well-written commentary. To me, this makes it very relevant for oncologists to think about their patient treatment options and also for journals to be more careful in accepting articles that make a difference in patient care. I am thinking that in a confirmatory trial, sponsors will be focusing on PFS and OS with more precise data.

In the commentary, the authors clearly mentioned gaps in statistical analysis due to limited data in the follow-up period.

Is there any way to request censored patient data from the original article authors? More importantly, in early trials, a patient's follow-up becomes very tough, just being the reason patients move on to explore alternative treatment options if they do not see early observable benefits. In that case, with the available data, it may be worth considering event-free survival and toxicities to help understand Sotorasib benefits.